Intermittent intravenous ibandronate therapy for osteoporosis
The author consecutively considers the introduction of intermittent use of ibandronate (I), by determining its single dose and annual cumulative dose. She presents data on the adequate antiresorptive activity of intermittent treatment, shows it necessary to design an intravenous dosage form of the d...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA-PRESS LLC
2008-09-01
|
| Series: | Современная ревматология |
| Online Access: | https://mrj.ima-press.net/mrj/article/view/175 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849303439681519616 |
|---|---|
| author | L I Alekseeva L I Alekseyeva |
| author_facet | L I Alekseeva L I Alekseyeva |
| author_sort | L I Alekseeva |
| collection | DOAJ |
| description | The author consecutively considers the introduction of intermittent use of ibandronate (I), by determining its single dose and annual cumulative dose. She presents data on the adequate antiresorptive activity of intermittent treatment, shows it necessary to design an intravenous dosage form of the drug and gives detailed data on the efficacy of parenteral I. The fact that the agent may be used in secondary (steroidal) osteoporosis is provided. There is evidence that the risk of extravertebral and all clinical fractures reduces when I is intravenously injected in a dose of 3 mg quarterly and orally administered in a dose of 150 mg monthly. |
| format | Article |
| id | doaj-art-1d55e0f298de4ca68d3f0ec22ca892d5 |
| institution | Kabale University |
| issn | 1996-7012 2310-158X |
| language | Russian |
| publishDate | 2008-09-01 |
| publisher | IMA-PRESS LLC |
| record_format | Article |
| series | Современная ревматология |
| spelling | doaj-art-1d55e0f298de4ca68d3f0ec22ca892d52025-08-20T03:59:57ZrusIMA-PRESS LLCСовременная ревматология1996-70122310-158X2008-09-0123555910.14412/1996-7012-2008-4901480Intermittent intravenous ibandronate therapy for osteoporosisL I AlekseevaL I AlekseyevaThe author consecutively considers the introduction of intermittent use of ibandronate (I), by determining its single dose and annual cumulative dose. She presents data on the adequate antiresorptive activity of intermittent treatment, shows it necessary to design an intravenous dosage form of the drug and gives detailed data on the efficacy of parenteral I. The fact that the agent may be used in secondary (steroidal) osteoporosis is provided. There is evidence that the risk of extravertebral and all clinical fractures reduces when I is intravenously injected in a dose of 3 mg quarterly and orally administered in a dose of 150 mg monthly.https://mrj.ima-press.net/mrj/article/view/175 |
| spellingShingle | L I Alekseeva L I Alekseyeva Intermittent intravenous ibandronate therapy for osteoporosis Современная ревматология |
| title | Intermittent intravenous ibandronate therapy for osteoporosis |
| title_full | Intermittent intravenous ibandronate therapy for osteoporosis |
| title_fullStr | Intermittent intravenous ibandronate therapy for osteoporosis |
| title_full_unstemmed | Intermittent intravenous ibandronate therapy for osteoporosis |
| title_short | Intermittent intravenous ibandronate therapy for osteoporosis |
| title_sort | intermittent intravenous ibandronate therapy for osteoporosis |
| url | https://mrj.ima-press.net/mrj/article/view/175 |
| work_keys_str_mv | AT lialekseeva intermittentintravenousibandronatetherapyforosteoporosis AT lialekseyeva intermittentintravenousibandronatetherapyforosteoporosis |